Sunshine Biopharma Inc. (SBFM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sunshine Biopharma Inc. on September 11, 2026. The Company is incorporated in Colorado and maintains its principal executive offices in Fort Lauderdale, Florida. Its common stock (SBFM) and common stock purchase warrants (SBFMW) are registered on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than comprehensive financial results.
Material Changes
Item 8.01 (Other Events) discloses a material change to the Company's capital structure:
- Warrant Price Adjustment: Due to recent sales of common stock under the Company's previously disclosed at-the-market offering, the exercise price of the outstanding Series B Warrants has been reduced to $1.2046.
- Future Adjustments: The new exercise price is subject to further adjustment as set forth under the terms of the Series B Warrants.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed beyond the standard warrant adjustment mechanism triggered by the at-the-market offering.
Investor Verification Checklist
- Verify the current trading price of SBFM relative to the new Series B Warrant exercise price of $1.2046.
- Review the specific terms of the Series B Warrants to understand the mechanics of future price adjustments.
- Confirm the volume and pricing of recent at-the-market offerings that triggered this adjustment.